Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Mar;57(3):174-184.
doi: 10.1007/s00535-022-01851-1. Epub 2022 Jan 28.

Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)

Hiroshi Nakase  1 , Yuki Hayashi  2 , Daisuke Hirayama  2 , Takayuki Matsumoto  3 , Minoru Matsuura  4 , Hideki Iijima  5 , Katsuyoshi Matsuoka  6 , Naoki Ohmiya  7 , Shunji Ishihara  8 , Fumihito Hirai  9 , Daiki Abukawa  10 , Tadakazu Hisamatsu  4 ; J-COSMOS group
Collaborators, Affiliations
Observational Study

Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)

Hiroshi Nakase et al. J Gastroenterol. 2022 Mar.

Abstract

Background: The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear.

Methods: This study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed.

Results: From 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies.

Conclusion: Age, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients.

Keywords: Anti-TNF-α antibodies; COVID-19; Inflammatory bowel disease; SARS-CoV-2; Steroid.

PubMed Disclaimer

Conflict of interest statement

Dr. Hiroshi Nakase (HN) reports receiving personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., Celgene K.K., EA Pharma Co., Ltd., Zeria Pharmaceutical CO., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., D Daiichi Sankyo Co., Ltd., JIMRO Co., Ltd., as well as grants for commissioned/joint research from Hoya Group Pentax Medical, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company. Dr Yuki Hayashi (YH) and Dr. Daisuke Hirayama (DH) report no receipt of personal fees from any pharmaceutical companies. Dr. Takayuki Matsumoto (TM) reports receipt of personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and JIMRO Co., Ltd. Dr. Minoru Matsuura (MM) reports receipt of personal fees from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Dr. Hideki Iijima (HI) report personal fees from AbbVie Inc, Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., Eisai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Mochida Pharmaceutical Co. Ltd., and research grants from AbbVie Inc., Nippon Kayaku Co., Ltd, Daiichi Sankyo Company, Ltd. Dr. Katsuyoshi Matsuoka (KM) reports personal fees from AbbVie Inc, Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Pfizer Lnc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and commercial research funding from Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd, AbbVie GK, Nippon Kayaku Co., Ltd., EA pharma Co., Ltd. Dr. Naoki Ohmiya (NO) reports receiving grants for commissioned/joint research from Nippon Kayaku Co., Ltd. EA Pharma Co., Ltd., EA Pharma Co., Ltd. Dr. Shunji Ishihara (SI) reports receipt of personal fees from Takeda Pharmaceutical Co. Ltd and receiving grants for commissioned/joint research from Takeda Pharmaceutical Co. Ltd, Nippon Kayaku Co., Ltd., Astellas Pharma Inc., EA Pharma Co., Ltd., Zeria Pharmaceutical CO., Ltd., Daiichi Sankyo Company, Ltd., and JIMRO Co., Ltd. Dr. Fumihito Hirai (FH) reports receipt of personal fees from AbbVie GK, EA pharma Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd. Dr. Daiki Abukawa reports no receipt of personal fees from any pharmaceutical companies. Dr. Tadakazu Hisamatsu (TH) receipt of personal fees from EA pharma Co. Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nichi-lko Pharmaceutical Co., Ltd., and commercial research funding from EA pharma Co., Ltd., AbbVie GK, Daiichi-Sankyo Co., Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co.,Ltd., Mochida Pharmaceutical Co., Ltd., and ZERIA Pharmaceutical Co., Ltd.

Figures

Fig. 1
Fig. 1
(A) Age distribution of Japanese IBD patients with COVID-19. (B) Transition of the number of Japanese IBD with COVID-19
Fig. 2
Fig. 2
(A) SARS-CoV-2 vaccination coverage (%) in Japanese population. Vaccination coverage was calculated among all citizens who were eligible for vaccination, using vaccination records published by the Cabinet Secretariat Office, based on reports from the Vaccination Record System. (B) Transition of the number of Japanese IBD with COVID-19 stratified by age
Fig. 3
Fig. 3
Treatment of Japanese IBD at the diagnosis of COVID-19. A blue bar indicated treatment continuation, an orange bar indicated treatment discontinuation, and a gray bar indicated additional treatment
See this image and copyright information in PMC

References

    1. Sungnak W, Huang N, Bécavin C, et al. SuSARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681–687. doi: 10.1038/s41591-020-0868-6. - DOI - PMC - PubMed
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica... (2020).
    1. Centers for Disease Control and Prevention (CDC). People Who Are at Higher Risk for Severe Illness. 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-....
    1. Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:1393–1399. doi: 10.1136/annrheumdis-2020-217984. - DOI - PubMed

Publication types